0001104659-25-056986.txt : 20250605 0001104659-25-056986.hdr.sgml : 20250605 20250605214438 ACCESSION NUMBER: 0001104659-25-056986 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250603 FILED AS OF DATE: 20250605 DATE AS OF CHANGE: 20250605 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Iwicki Mark T CENTRAL INDEX KEY: 0001415537 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-38150 FILM NUMBER: 251028731 MAIL ADDRESS: STREET 1: 84 WATERFORD DRIVE CITY: MARLBOROUGH STATE: MA ZIP: 01752 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: KALA BIO, Inc. CENTRAL INDEX KEY: 0001479419 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 270604595 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1167 MASSACHUSETTS AVENUE CITY: ARLINGTON STATE: MA ZIP: 02476 BUSINESS PHONE: 781-996-5252 MAIL ADDRESS: STREET 1: 1167 MASSACHUSETTS AVENUE CITY: ARLINGTON STATE: MA ZIP: 02476 FORMER COMPANY: FORMER CONFORMED NAME: Kala Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20091223 4/A 1 tm2517328-2_4aseq1.xml OWNERSHIP DOCUMENT X0508 4/A 2025-06-03 2025-06-04 0 0001479419 KALA BIO, Inc. KALA 0001415537 Iwicki Mark T C/O KALA BIO, INC. 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476 1 0 0 0 0 Common Stock 2025-06-03 4 S 0 10866 3.74 D 269210 D This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 9, 2020 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units ("RSUs") granted on May 31, 2023. This amendment is being filed solely to correct the nature of the transaction reported in Column 4 of Table I of the Form 4 filed by the Reporting Person on June 4, 2025. As reported in this amendment, such transaction resulted in a "disposition" of common stock by the Reporting Person and not an "acquisition" as previously reported. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.52 to $4.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Includes 154,042 unvested RSUs. /s/ Mary Reumuth, Attorney-in-Fact 2025-06-05